Organisation paid for research Program year 2022 Source: CMS Open Payments

Compassionate Care Research

Neither a doctor nor a teaching hospital

Research payments

$44,755

14 payments

Through program year 2022, Compassionate Care Research is reported as receiving $44,755 in research payments, across 14 payments.

By program year

2 rows
Year Kind Amount Payments
2022 Research $23,335 10
2019 Research $21,420 4

Breakdown

Who paid Research payments · program years 2019–2022
  1. Takeda Pharmaceuticals U.S.A., Inc. $44,755 14 payments
Studies the money was for Research payments · program years 2019–2022
  1. A Trial of AP32788 in Non-Small Cell Lung Cancer $11,131 1 payment
  2. TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom $10,290 3 payments
  3. A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine As First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Or Low-Blast Acute Myelogenous Leukemia $9,500 4 payments
  4. A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia $6,709 3 payments
  5. A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Mln9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma $5,626 2 payments
  6. A Phase 1/1B Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, Or Advanced Solid Tumors With Severe Renal Impairment Or Mild Or Moderate Hepatic Impairment $1,500 1 payment
What the money was spent on Research payments · program years 2019–2022
  1. Other $21,420 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record